%0 Journal Article
%T Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
%A James J. Vredenburgh
%A Poorva Bindal
%A Vinay Mathew Thomas
%J Archive of "Case Reports in Oncology".
%D 2019
%R 10.1159/000496984
%X Meningiomas are primary CNS tumors that arise from the arachnoid layer of the meninges. Genomic sequencing has revealed that NF2 mutations are the most common genetic alteration seen in meningiomas. Meningiomas although usually low grade, can sometimes progress to high grade. A patient who had several recurrences of meningiomas since childhood presented with recurrent headaches. Imaging showed that he had another recurrence of a meningioma. He underwent surgery for resection of the meningioma and histopathology showed NF2 mutation. He was started on everolimus and bevacizumab with good effect. Studies have shown that NF-2 mutated meningiomas have a good response to everolimus and bevacizumab with increased progression-free survival time and progression-free survival time at 6 months
%K NF-2 meningioma
%K Meningioma
%K Everolimus
%K Bevacizumab
%K Recurrent meningioma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477501/